We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+64.04%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.61B
AUM Growth
+$301M
Cap. Flow
-$35.3M
Cap. Flow %
-1.36%
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$114M
2
KRYS icon
Krystal Biotech
KRYS
+$66.7M
3
CTLT
CATALENT, INC.
CTLT
+$24.2M
4
COGT icon
Cogent Biosciences
COGT
+$23.6M
5
ZBH icon
Zimmer Biomet
ZBH
+$20.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$102M
2
ARGX icon
argenx
ARGX
+$48.6M
3
OSH
Oak Street Health, Inc.
OSH
+$41.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$31.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.11%
2 Industrials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
26
DELISTED
Ventyx Biosciences
VTYX
$30.8M 1.18%
940,493
+124,719
+15% +$4.3M
ADCT icon
27
ADC Therapeutics
ADCT
$146M
$30.2M 1.16%
14,049,935
+484,686
+4% +$1.09M
NRIX icon
28
Nurix Therapeutics
NRIX
$2.72B
$28.5M 1.1%
2,857,309
+107,925
+4% +$1.1M
IGMS
29
DELISTED
IGM Biosciences
IGMS
$27.4M 1.05%
2,971,542
-362,813
-11% -$4.06M
SYK icon
30
Stryker
SYK
$127B
$26.2M 1.01%
85,899
-50,565
-37% -$14.6M
RPTX
31
DELISTED
Repare Therapeutics
RPTX
$25.7M 0.99%
2,428,335
-104,715
-4% -$1.08M
COGT icon
32
Cogent Biosciences
COGT
$6.02B
$24.3M 0.93%
+2,053,333
New +$23.6M
CRL icon
33
Charles River Laboratories
CRL
$13.9B
$24M 0.92%
114,351
-977
-0.8% -$194K
ZBH icon
34
Zimmer Biomet
ZBH
$19.2B
$22M 0.85%
+151,372
New +$20.6M
IQV icon
35
IQVIA
IQV
$43.1B
$21.2M 0.81%
94,409
+22,752
+32% +$4.57M
BSX icon
36
Boston Scientific
BSX
$67.9B
$21.2M 0.81%
391,178
+219,398
+128% +$11.5M
HUM icon
37
Humana
HUM
$46.3B
$20.7M 0.79%
46,310
-5,769
-11% -$2.9M
VERV
38
DELISTED
Verve Therapeutics
VERV
$19.9M 0.76%
1,061,960
-58,719
-5% -$978K
TRDA icon
39
Entrada Therapeutics
TRDA
$273M
$19.9M 0.76%
1,311,572
-520,036
-28% -$7.16M
PRME icon
40
Prime Medicine
PRME
$655M
$19.4M 0.74%
1,324,350
-668,493
-34% -$9.33M
CABA icon
41
Cabaletta Bio
CABA
$529M
$17.7M 0.68%
1,370,299
+1,096,047
+400% +$11.9M
STTK icon
42
Shattuck Labs
STTK
$707M
$17.5M 0.67%
5,619,914
– –
ETNB
43
DELISTED
89bio
ETNB
$14.4M 0.55%
761,955
-138,045
-15% -$2.42M
GRTS
44
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.4M 0.51%
6,860,226
-66,700
-1% -$156K
ANNX icon
45
Annexon
ANNX
$942M
$12.3M 0.47%
3,503,190
– –
ABSI icon
46
Absci
ABSI
$1.49B
$12.2M 0.47%
8,031,094
– –
ALLK
47
DELISTED
Allakos
ALLK
$9.96M 0.38%
2,283,594
-2,583
-0.1% -$11.6K
STXS icon
48
Stereotaxis
STXS
$145M
$9.75M 0.37%
6,373,898
+4,886,403
+328% +$9.06M
ATRA icon
49
Atara Biotherapeutics
ATRA
$92.3M
$9.74M 0.37%
241,925
+17,443
+8% +$986K
ALXO icon
50
ALX Oncology
ALXO
$277M
$9.64M 0.37%
1,283,289
+696,312
+119% +$4.56M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2023 Portfolio in Review

As of Q2 2023, Redmile Group held 82 positions worth $2.61B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group's Q2 2023 filing shows 6 new, 24 increased, 27 reduced and 10 closed positions. Its largest new stake was Cogent Biosciences: 2,053,333 shares worth $24.3M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $102M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Redmile Group's largest Q2 2023 buy was Cogent Biosciences: 2,053,333 shares worth $24.3M.
  • Redmile Group added most to Immunogen Inc in Q2 2023, an estimated $114M increase.
  • Redmile Group's biggest Q2 2023 reduction was Stevanato, cutting an estimated $19.2M.
  • Redmile Group fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $102M.
  • Redmile Group's ten largest holdings make up 53% of its $2.61B portfolio in Q2 2023.
  • Redmile Group opened 6 new positions and closed 10 in Q2 2023.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.61B.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.